Alzheimer's Research Is Moving Toward Earlier Intervention: Can Prevention Begin Before Memory Changes?

Alzheimer's Research Is Entering an Earlier Stage of Intervention

Alzheimer's disease has traditionally entered clinical care when patients or their families begin noticing changes in memory, reasoning, or everyday function. Research over the past several decades has shown that the neurological processes contributing to those changes may begin much earlier, with amyloid accumulation, tau pathology, inflammatory activity, and alterations in brain metabolism developing over years before dementia becomes clinically apparent.

This understanding has gradually changed the direction of Alzheimer's research. Rather than concentrating exclusively on slowing decline after cognitive symptoms have emerged, investigators are asking whether treatment during an earlier biological stage might preserve more neurological function. The October 8, 2026, clinical-trials update published by Being Patient illustrates how substantially the field has expanded. Its independent tracker identified 94 late-stage Alzheimer's trials recruiting participants as of September 2026, including 11 categorized as prevention studies involving people with genetic susceptibility, elevated biomarkers, or inherited forms of the disease.

The research pipeline includes new anti-amyloid therapies, approaches targeting tau and other disease mechanisms, oral medications, neurological devices, and drugs being investigated beyond their original therapeutic indications. The trial count represents scientific activity rather than established clinical success, but the increasing emphasis on people who have not yet developed cognitive symptoms reflects a meaningful change in how researchers are approaching the disease.

Source: Alzheimer's Clinical Trials — October 2026 Update

What Happens Before Alzheimer's Symptoms Appear?

The biological changes associated with Alzheimer's disease involve abnormal accumulation and processing of amyloid-beta and tau proteins, although the clinical course of the disease is influenced by genetic susceptibility, vascular health, inflammatory signaling, cellular metabolism, and the capacity of neural networks to compensate for injury. Amyloid-beta may accumulate into plaques, while abnormal tau can disrupt neuronal structure and function. These processes interact with synaptic communication and immune activity, eventually contributing to neurological damage in susceptible individuals.

Improved biomarkers have made it possible to identify some of these changes before obvious cognitive impairment develops. For researchers, this creates an opportunity to investigate whether intervention at an earlier stage can alter the subsequent course of disease. It also introduces uncertainty into clinical decision-making because detectable pathology does not necessarily determine how rapidly a person will decline or whether they will develop dementia during their lifetime.

Alzheimer's pathology and dementia are related but distinct clinical concepts. Dementia describes cognitive impairment severe enough to interfere with independent daily function, and Alzheimer's disease is only one of its possible causes. Vascular disease, Lewy body disease, frontotemporal degeneration, and other neurological conditions may produce cognitive impairment independently or alongside Alzheimer's pathology. Age, cognitive reserve, existing vascular injury, and other medical conditions can influence the expression of cognitive symptoms even when Alzheimer's-associated biomarkers are present.

Earlier recognition may ultimately expand therapeutic opportunities, but the clinical value of testing must be considered alongside the accuracy of the result, the uncertainty of future progression, available interventions, and the consequences of identifying a biological risk in someone who may remain cognitively healthy for many years.

The Emerging Prevention Trials

Trontinemab: Investigating Amyloid Treatment Before Symptoms

Trontinemab is an investigational anti-amyloid antibody designed to improve medication delivery across the blood-brain barrier. This approach is being studied because the brain's protective vascular barrier limits the delivery of many large therapeutic molecules, including conventional monoclonal antibodies. Early investigations have reported substantial reductions in measured amyloid burden, supporting further trials in people with early Alzheimer's disease.

The PrevenTRON prevention program is also investigating trontinemab in approximately 1,600 cognitively unimpaired participants considered to be at elevated risk based on biological screening. Unlike traditional symptomatic-treatment studies, these participants do not need to have established dementia or noticeable memory impairment. Investigators are examining whether intervention against amyloid pathology at this stage can meaningfully delay or prevent subsequent clinical decline.

Amyloid reduction provides evidence that a treatment is reaching its biological target, but the clinical significance of that reduction must be established through cognitive and functional outcomes. Earlier intervention is an attractive hypothesis because neurological injury may be less advanced, although the balance of treatment benefit and risk becomes especially important when participants are functioning normally at enrollment.

Obicetrapib: Cholesterol Biology Enters Alzheimer's Prevention Research

Obicetrapib is an investigational cholesterol-lowering medication that inhibits cholesteryl ester transfer protein, or CETP. In cardiovascular lipid research, investigators observed changes in Alzheimer's-associated blood biomarkers among people receiving the medication, with exploratory analyses suggesting that certain effects might be more pronounced in participants carrying two copies of APOE4. These observations helped motivate a Phase 2 prevention study involving approximately 400 APOE4 carriers with blood biomarkers suggesting elevated Alzheimer's risk.

The biological rationale extends beyond circulating cholesterol concentrations. APOE participates in lipid transport within the central nervous system, where lipid handling is essential to neuronal membranes, synaptic function, inflammatory regulation, and several processes involved in protein clearance. Researchers are interested in whether modifying lipid-related pathways could influence Alzheimer's-associated neurological changes, particularly in people with genetic susceptibility involving APOE.

The findings remain preliminary because changes in Alzheimer's blood biomarkers do not establish that obicetrapib can prevent dementia. The trial is intended to investigate that possibility rather than confirm an established neurological indication. Although the medication's lipid effects are relevant to cardiovascular medicine, the proposed Alzheimer's application requires separate evidence demonstrating meaningful cognitive benefit and acceptable safety.

APOE4: Genetic Susceptibility Without Genetic Certainty

Apolipoprotein E is involved in the transport and regulation of lipids within the body and brain. The three common variants, APOE2, APOE3, and APOE4, have different associations with late-onset Alzheimer's susceptibility. Carrying APOE4 increases population-level risk, with two copies generally conferring greater susceptibility than one, although the magnitude varies with age, ancestry, sex, and other individual characteristics. APOE4 is neither necessary nor sufficient for developing Alzheimer's disease, and many carriers remain cognitively healthy throughout life.

The distinction between susceptibility and diagnosis is particularly important as consumer genetic testing becomes more accessible. A genetic result cannot determine an individual's future cognitive status, and its clinical interpretation should include family history, cardiovascular and metabolic health, existing cognitive findings, and the reason testing was performed. For otherwise healthy adults, APOE status does not establish a validated personalized medication or supplement protocol capable of preventing dementia.

Genetic information can have more specific implications when treatment is being considered. APOE4 carriers, particularly those carrying two copies, have an increased risk of amyloid-related imaging abnormalities during treatment with certain anti-amyloid antibodies. These abnormalities may involve brain edema or bleeding, making genetic counseling, informed consent, and appropriate neurological monitoring important components of treatment planning.

HormoneSynergy® examines this relationship in more detail in APOE4 Is Not a Diagnosis: What Your Alzheimer's Risk Gene Really Means, including the overlap between genetic susceptibility, cardiovascular risk, and brain health.

Why Cardiovascular and Brain Health Are Closely Connected

The brain receives a substantial proportion of resting cardiac output and depends on continuous regulation of blood flow, oxygen delivery, and metabolic substrates. Its vascular network must support changing neuronal energy demands while protecting delicate brain tissue from fluctuations in pressure and circulating substances. Over time, hypertension, diabetes, smoking, atherosclerosis, and other cardiovascular risk factors can contribute to small-vessel injury, altered vascular responsiveness, ischemic damage, and changes in white-matter integrity.

In older adults, vascular injury often coexists with Alzheimer's pathology, creating a clinical picture in which cognitive decline reflects more than one disease process. This is one reason cardiovascular risk assessment belongs in the discussion of cognitive aging even when an individual has a family history or genetic susceptibility associated with Alzheimer's disease.

ApoB-containing lipoproteins contribute to atherosclerotic plaque development, while elevated LDL cholesterol in midlife has been identified as a potentially modifiable dementia risk factor in major research reviews. ApoB is useful for assessing atherogenic particle burden and cardiovascular risk, although it is not an Alzheimer's biomarker, and no specific ApoB treatment threshold has been demonstrated to independently prevent Alzheimer's disease.

Management of blood pressure, diabetes, smoking, and lipid-related cardiovascular risk is supported by substantial clinical evidence. The implications for cognitive health are biologically and epidemiologically important, particularly because vascular disease can independently impair cognition and may compound the effects of neurodegenerative pathology. The objective is to manage clinically established cardiovascular risk while recognizing its relevance to the brain rather than assuming that any one cardiovascular intervention directly prevents Alzheimer's disease.

Additional discussion is available in the HormoneSynergy® Preventive Cardiology and Longevity Medicine resource.

Insulin Resistance and the Aging Brain

Brain metabolism has become an important area of Alzheimer's investigation because neurons require sustained energy availability to maintain electrical activity, synaptic communication, and cellular repair. Alterations in cerebral glucose utilization are among the metabolic abnormalities observed in Alzheimer's disease. Insulin participates in neural signaling and may influence synaptic function, inflammatory regulation, and cellular metabolism, prompting research into the relationship between impaired insulin signaling and cognitive decline.

Type 2 diabetes is associated with increased dementia risk, and its neurological implications are difficult to separate entirely from the vascular and metabolic conditions that commonly accompany it. Hypertension, visceral adiposity, dyslipidemia, systemic inflammation, and insulin resistance may contribute through overlapping mechanisms. The expression "type 3 diabetes" has sometimes been used to describe this research, but it is not an accepted clinical diagnosis and does not adequately characterize the complexity of Alzheimer's pathology.

For preventive assessment, fasting glucose and hemoglobin A1c remain established measurements for identifying impaired glucose regulation, prediabetes, and diabetes. Fasting insulin and HOMA-IR can provide additional metabolic information in selected patients, although neither is validated for diagnosing Alzheimer's disease or predicting an individual's future cognitive decline. Triglycerides, blood pressure, visceral fat, body composition, physical activity, and sleep quality help place these findings within the broader clinical picture.

This integrated metabolic approach is discussed further in Metabolic Health and Insulin Resistance: A Longevity Medicine Guide.

GLP-1 Medications and Alzheimer's Disease

GLP-1 receptor agonists have generated considerable interest in neurological research because their established effects on glucose regulation, weight, and cardiovascular physiology intersect with pathways implicated in brain aging. Experimental investigations have explored possible effects involving neuroinflammation, neuronal signaling, and cellular metabolism, while observational human research has reported associations between GLP-1 treatment and selected neurological outcomes. These findings provided a rationale for testing whether metabolic therapies might influence Alzheimer's disease progression.

The EVOKE and EVOKE+ Phase 3 trials investigated oral semaglutide in people with early symptomatic Alzheimer's disease but did not demonstrate a significant slowing of clinical progression on their primary outcomes. These results place an important boundary around the neurological interpretation of GLP-1 research. Semaglutide continues to have established benefits for appropriate patients with obesity, diabetes, and certain cardiovascular or kidney conditions, but its metabolic effects have not translated into demonstrated treatment or prevention of Alzheimer's disease.

Research may continue to examine whether different populations, treatment stages, or related medications produce other neurological outcomes. In clinical practice, GLP-1 therapy remains most appropriately grounded in established indications, with attention to adequate nutrition, resistance training, muscle preservation, and sustained metabolic health rather than an assumed cognitive benefit.

What Current Alzheimer's Treatments Have Established

The development of lecanemab and donanemab represents an important advance because randomized clinical trials have demonstrated modest slowing of decline in appropriately selected patients with early symptomatic Alzheimer's disease. These anti-amyloid antibodies provide evidence that modifying disease-associated pathology can influence clinical progression, although neither reverses established neurological injury and the magnitude of benefit varies among patients.

Both therapies require confirmation of amyloid pathology, careful clinical selection, and ongoing monitoring. Amyloid-related imaging abnormalities, known as ARIA, may involve brain swelling or bleeding, and their occurrence is influenced by factors that include APOE genotype. MRI surveillance and discussion of treatment risks are therefore integral to care.

These medications are not established preventive treatments for otherwise healthy adults with APOE4 or a family history of Alzheimer's disease. The newer prevention trials are investigating whether the balance of benefit and risk changes when biological intervention occurs before symptoms, a question that remains open despite progress in treating early symptomatic disease.

Blood Biomarkers: Opportunities and Limits of Earlier Recognition

Blood-based biomarkers are becoming increasingly useful in Alzheimer's research and clinical evaluation because they can provide information about disease-associated biology without immediately requiring cerebrospinal fluid sampling or amyloid PET imaging. Measurements involving phosphorylated tau, particularly p-tau217, have demonstrated encouraging diagnostic performance in appropriately studied populations, while other assays examine amyloid-beta peptide ratios and markers of neurological injury.

Their clinical value depends on the population being tested and the accuracy of the specific assay. A biomarker that performs well among symptomatic patients referred to a specialist memory clinic may have a substantially different predictive value when applied to cognitively healthy adults with a low probability of disease. Even when Alzheimer's-associated pathology is identified accurately, the result does not necessarily establish when meaningful impairment will occur.

Testing also requires consideration of false-positive and false-negative results, individual anxiety, the availability of confirmatory evaluation, and whether the result will influence a decision supported by clinical evidence. Routine blood-biomarker screening of every healthy adult over a particular age is therefore not an established component of preventive longevity medicine.

For patients experiencing persistent or progressive cognitive symptoms, validated biomarkers may help clarify the likelihood of Alzheimer's pathology when interpreted with cognitive assessment, neurological findings, medical history, and appropriate imaging or confirmatory testing. The purpose is to support a clinically meaningful diagnosis rather than to treat an isolated laboratory result.

The Role of Cognitive Baseline Testing

Memory and concentration changes can arise from many conditions other than neurodegenerative disease. Sleep disturbance, depression, anxiety, hearing impairment, medication effects, thyroid dysfunction, vitamin B12 deficiency, and other medical problems can influence attention, processing speed, and memory. Persistent or progressive symptoms deserve medical evaluation, but their presence does not automatically indicate Alzheimer's disease.

Objective cognitive testing can characterize performance across several domains, including memory, attention, executive function, processing speed, and reaction time. When there is a clinical reason to assess or follow cognition, establishing a baseline can provide useful context for subsequent changes. HormoneSynergy® uses CNS Vital Signs neurocognitive testing when appropriate as part of comprehensive preventive assessment.

Computerized cognitive testing does not diagnose Alzheimer's disease independently. Interpretation requires attention to fatigue, sleep, mood, educational background, medication effects, practice effects, and testing conditions. Longitudinal evaluation may be informative when results are considered alongside medical history and other clinical findings, while concerning abnormalities or changes affecting daily function may warrant formal neuropsychological testing, neurological consultation, or appropriate brain imaging.

Sleep, Exercise, Hearing, and Nutrition in Cognitive Prevention

The growing Alzheimer's treatment pipeline deserves attention, although it should be viewed alongside the substantial evidence connecting cognitive health with established aspects of medical care and everyday physiology. The 2024 Lancet Commission on dementia prevention identified potentially modifiable contributors throughout the lifespan, including hypertension, elevated LDL cholesterol, diabetes, smoking, physical inactivity, hearing loss, obesity, depression, social isolation, excessive alcohol consumption, and other factors. These associations arise from different forms of evidence and should not be interpreted as a guarantee that correcting every risk factor will prevent dementia.

Many relevant interventions already provide benefits independent of Alzheimer's disease. Regular aerobic activity supports cardiovascular function and metabolic regulation, while resistance training helps preserve skeletal muscle, strength, and physical independence. Both are important components of healthy aging, particularly when insulin resistance, declining mobility, or reduced physical capacity are present.

Sleep quality also deserves clinical consideration. Obstructive sleep apnea can contribute to fragmented sleep, daytime cognitive symptoms, hypertension, and vascular stress, making appropriate evaluation and treatment relevant to patients with suggestive symptoms or medical risk factors. Hearing and vision problems can increase the demands of everyday cognitive tasks and influence communication, social participation, and quality of life.

Nutritional patterns emphasizing vegetables, legumes, whole grains, nuts, appropriate protein intake, unsaturated fats, and other elements of Mediterranean-style eating are consistent with established cardiometabolic prevention principles. Although individual foods and supplements are frequently marketed for Alzheimer's prevention, no dietary pattern or supplement combination has been demonstrated to guarantee protection against dementia, including among APOE4 carriers.

HormoneSynergy® explores these relationships in Brain Health and Longevity: Prevention, Metabolism, Sleep, Heart Health, and Muscle Aging.

Repurposed Medications and the Search for Additional Treatments

Alongside therapies developed specifically for Alzheimer's pathology, researchers continue investigating medications used for other conditions, including metformin, atomoxetine, and levetiracetam. The rationale for repurposing drugs is partly practical: established medications often have substantial information available about their pharmacology, manufacturing, dosing, and safety within approved indications. Their effects on metabolic regulation, neurological signaling, or inflammatory pathways may also provide a biological reason to investigate new applications.

Evidence of benefit in another condition does not establish efficacy in Alzheimer's disease. A medication may change a disease-associated biomarker without preserving cognitive performance, while another may improve particular symptoms without modifying neurodegenerative progression. Randomized trials are necessary to determine whether these interventions can achieve meaningful neurological outcomes, especially when their proposed use involves otherwise healthy people at elevated but uncertain future risk.

Repurposing remains scientifically worthwhile, but clinical familiarity with a medication should not become a substitute for evidence supporting its new indication. The potential benefit must justify the risks associated with treatment, the duration of exposure, and the clinical characteristics of the intended population.

What Prevention Trials May Change

Trials involving cognitively unimpaired participants face challenges that differ substantially from studies of established Alzheimer's disease. Some people with genetic susceptibility or positive biomarkers may remain cognitively healthy for many years, making it difficult to determine whether a treatment has prevented decline without large study populations and prolonged follow-up. Investigators must also consider the consequences of exposing participants to medication risks, repeated imaging, and potentially invasive investigations when their future clinical course is uncertain.

The eventual success of prevention research will depend on outcomes that extend beyond changes in amyloid or tau measurements. Delaying cognitive deterioration, preserving independence, and maintaining daily function are more meaningful than producing a favorable biomarker result without an associated clinical benefit. Improved testing may help select participants who are more likely to benefit, although earlier biological identification alone does not ensure effective prevention.

The HormoneSynergy® Approach

HormoneSynergy® evaluates cognitive health within the broader context of cardiovascular, metabolic, hormonal, and functional aging. Under the clinical leadership of Dr. Kathryn Retzler, preventive assessment considers neurological susceptibility alongside the medical conditions and physiological changes that may influence cognition over time. Blood pressure, lipid-related risk, glucose regulation, insulin resistance, visceral adiposity, physical fitness, sleep, nutritional status, and relevant family history provide a foundation for understanding potentially modifiable contributors.

APOE status can contribute additional information when genetic testing is clinically appropriate, but it is interpreted as susceptibility rather than a diagnosis. Similarly, objective cognitive testing may help establish a baseline or investigate concerns without establishing the presence of Alzheimer's pathology. The Optimal Aging Assessment integrates advanced laboratory evaluation, body composition measurements, vascular assessment, CNS Vital Signs testing, and an extended physician consultation so that individual findings can be interpreted within a patient's overall clinical picture.

Persistent or progressive cognitive changes require particular attention because they may reflect treatable medical conditions, neurological disease, or a combination of contributing factors. When indicated, additional evaluation may involve formal neuropsychological testing, brain imaging, Alzheimer's-specific biomarkers, or referral to an appropriate specialist. Such decisions depend on symptoms, clinical history, examination findings, and the likelihood that the result will influence care.

The prevention trials are encouraging because they may eventually expand the opportunities for intervention before substantial cognitive impairment develops. Until clinical benefit is established, HormoneSynergy® does not regard investigational Alzheimer's medications, routine biomarker screening of asymptomatic adults, or generalized brain supplement protocols as proven preventive treatment. Management of cardiovascular and metabolic risk, maintenance of physical capacity, appropriate sleep and nutritional care, and timely evaluation of cognitive concerns remain central to a responsible approach to cognitive longevity.

What the October 2026 Research Update Means for Preventive Medicine

The Alzheimer's clinical-trials pipeline now includes approaches directed at multiple biological pathways and different stages of disease, including people who have not yet experienced cognitive symptoms. Advances in biomarkers, genetic characterization, and disease-modifying treatments have made these investigations possible and may eventually lead to more precise methods of selecting patients for therapy.

The clinical implications will depend on whether earlier intervention can preserve memory and function with acceptable risks. For now, prevention cannot be reduced to a genetic result, an amyloid measurement, or a single medication. Cognitive health develops within a broader physiological context in which vascular disease, metabolic regulation, sleep, physical activity, sensory health, and other influences remain relevant throughout adulthood.

The new research offers reason for constructive interest while reinforcing a familiar principle of preventive medicine: identifying meaningful risks before substantial illness develops provides opportunities to address what is already understood, even as investigations continue into treatments that may become available in the future.

Related HormoneSynergy® Resources

• APOE4 Is Not a Diagnosis: What Your Alzheimer's Risk Gene Really Means
• Brain Health and Longevity: Prevention, Metabolism, Sleep, and Heart Health
• Brain Health and Cognitive Longevity: Protecting Memory and Focus
• Diet, Brain Health, and Longevity Medicine
• Brain Supplements and Longevity: What Actually Protects the Brain?
• Metabolic Health and Insulin Resistance
• Preventive Cardiology and Longevity Medicine
• Optimal Aging Assessment
• The HormoneSynergy® Longevity Medicine Model
• HormoneSynergy® Longevity Medicine Resource Library

Selected Research and Clinical References

1. Being Patient. Alzheimer's Clinical Trials: A 2026 Guide to the Drugs, Devices, and Studies in Development. October 8, 2026. 2026 clinical-trials update.
2. Cummings JL, et al. Alzheimer's disease drug development pipeline: 2026. 2026 pipeline review.
3. Livingston G, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet. 2024. Lancet Commission.
4. van Dyck CH, et al. Lecanemab in early Alzheimer's disease. New England Journal of Medicine. 2023;388:9–21. CLARITY AD trial.
5. Sims JR, et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512–527. TRAILBLAZER-ALZ 2 trial.
6. Alzheimer's Association. Clinical Trials Recruiting. Clinical research participation.

Frequently Asked Questions

Can Alzheimer's disease be detected before memory symptoms appear?

Biological changes associated with Alzheimer's disease can sometimes be identified before noticeable cognitive impairment develops, although biomarkers cannot establish precisely when or whether an individual will develop dementia. The usefulness of testing in asymptomatic people depends on the clinical context and the availability of appropriate counseling and follow-up.

Does APOE4 mean someone will develop Alzheimer's disease?

APOE4 increases susceptibility to late-onset Alzheimer's disease but does not diagnose the condition or guarantee that dementia will develop. Its interpretation should include family history, clinical findings, and other contributors to cognitive health.

Are medications proven to prevent Alzheimer's disease?

No medication has been established as a broadly effective preventive treatment for Alzheimer's disease in otherwise healthy, cognitively unimpaired adults. Clinical trials are investigating whether treating biological changes earlier in the disease course can delay or prevent subsequent cognitive decline.

Can insulin resistance increase dementia risk?

Type 2 diabetes and metabolic dysfunction are associated with increased dementia risk, potentially through overlapping vascular, metabolic, and inflammatory pathways. No single insulin measurement has been validated to predict Alzheimer's disease in an individual patient.

Can blood tests diagnose Alzheimer's disease?

Validated blood biomarkers can assist the evaluation of Alzheimer's pathology in appropriate clinical populations, especially patients with cognitive impairment. Their interpretation depends on assay performance, symptoms, examination findings, and whether additional confirmation is necessary. Routine screening of all healthy adults is not established practice.

Do GLP-1 medications prevent Alzheimer's disease?

GLP-1 medications have established benefits in selected metabolic and cardiovascular conditions, but they have not been demonstrated to prevent Alzheimer's disease. Large randomized trials of oral semaglutide in early symptomatic Alzheimer's did not show significant slowing of clinical progression on their primary outcomes.

What can be done now to support cognitive health?

Evidence-based priorities include cardiovascular and metabolic risk management, regular physical activity, smoking avoidance, appropriate assessment of sleep and sensory health, sound nutrition, and medical evaluation of persistent or progressive cognitive symptoms. These interventions also provide important benefits for overall health and physical function.

Editorial Transparency: This article examines published clinical research and active investigational programs. Clinical-trial enrollment figures reflect the September 2026 research snapshot and may change. Inclusion of a drug or intervention in a clinical trial does not establish therapeutic benefit or imply endorsement by HormoneSynergy®.

About HormoneSynergy®: HormoneSynergy® provides evidence-based preventive longevity medicine in Portland and Lake Oswego, Oregon, under the clinical leadership of Dr. Kathryn Retzler. The practice integrates advanced assessment, individualized treatment, and longitudinal evaluation of cardiovascular, metabolic, hormonal, cognitive, and physical health.

Medical Disclaimer: This article is educational and does not replace individualized medical advice. Alzheimer's biomarkers, genetic testing, neurological assessments, and investigational treatments require appropriate clinical interpretation. Persistent or progressive cognitive symptoms should be evaluated by a qualified healthcare professional.